Iambic CEO on taking an AI drug company public

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 16 Oct, 16:10 UTC

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.